New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy

Drug Resistance Updates

Volumn 29, Issue , 2016, Pages 90-106

  Gabizon, Alberto A ^a,b   Patil, Yogita ^b   La Beck, Ninh M ^c  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Anthracyclines; Chemotherapy; Drug delivery; Liposome; Nanomedicine

Indexed keywords

DOXORUBICIN; LIPOSOME; PLASMA PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG CLEARANCE; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE SYSTEM; KAPOSI SARCOMA; META ANALYSIS (TOPIC); NANOMEDICINE; NEOPLASM; NONHUMAN; OVARY CANCER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONAL PERFUSION; REVIEW; SOFT TISSUE SARCOMA; THERANOSTIC NANOMEDICINE; ANALOGS AND DERIVATIVES; BREAST TUMOR; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; FEMALE; HEMATOLOGIC DISEASE; MALE; METABOLISM; MULTIPLE MYELOMA; OVARY TUMOR; PATHOLOGY; TRENDS;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG COMPOUNDING; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LIPOSOMES; MALE; MULTIPLE MYELOMA; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; SARCOMA, KAPOSI; THERANOSTIC NANOMEDICINE;

EID: 84994614344     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2016.10.003     Document Type: Review

References (150)

1. Abu Lila, A.S., Kiwada, H., Ishida, T., The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J. Control. Release 172 (2013), 38–47.
2. Adachi, K., Tamada, K., Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 106 (2015), 945–950.
3. Ahmed, M., Moussa, M., Goldberg, S.N., Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem. Phys. Lipids 165 (2012), 424–437.
4. Alba, E., Ruiz-Borrego, M., Margelí, M., Rodríguez-Lescure, A., Sánchez-Rovira, P., RuizA, Mel-Lorenzo, J.R., Ramos-Vázquez, M., Ribelles, N., Calvo, E., Casado, A., Márquez, A., Vicente, D., García-Sáenz, J.A., Martín, M., Maintenance treatment with pegylatedliposomal doxorubicin versus observation following induction chemotherapy formetastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res. Treat. 122 (2010), 169–176.
5. Alberts, D.S., Muggia, F.M., Carmichael, J., Winer, E.P., Jahanzeb, M., Venook, A.P., Skubitz, K.M., Rivera, E., Sparano, J.A., DiBella, N.J., Stewart, S.J., Kavanagh, J.J., Gabizon, A.A., Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin. Oncol. 31 (2004), 53–90.
6. Alberts, D.S., Liu, P.Y., Wilczynski, S.P., Clouser, M.C., Lopez, A.M., Michelin, D.P., Lanzotti, V.J., Markman, M., Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol. Oncol. 108 (2008), 90–94.
7. Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65 (2013), 36–48.
8. Armstrong, J.K., Leger, R., Wenby, R.B., Meiselman, H.J., Garratty, G., Fisher, T.C., Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood, 102, 2003, 556a.
9. Ashley, N., Poulton, J., Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem. Biophys. Res. Commun. 378 (2009), 450–455.
10. Assaraf, Y.G., Leamon, C.P., Reddy, J.A., The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist. Updates 17 (2014), 89–95.
11. Bangham, A.D., Standish, M.M., Watkins, J.C., Diffusion of univalent ions across thelamellae of swollen phospholipids. J. Mol. Biol. 13 (1965), 238–252.
12. ®—the first FDA-approved nano-drug: lessons learned. J. Control. Release 160 (2012), 117–134.
13. Briasoulis, E., Karavasilis, V., Tzamakou, E., Rammou, D., Soulti, K., Piperidou, C., Pavlidis, N., Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother. Pharmacol. 53 (2004), 452–457.
14. Caron, W.P., Lay, J.C., Fong, A.M., La-Beck, N.M., Kumar, P., Newman, S.E., Zhou, H., Monaco, J.H., Clarke-Pearson, D.L., Brewster, W.R., Van Le, L., Bae-Jump, V.L., Gehrig, P.A., Zamboni, W.C., Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. J. Pharmacol. Exp. Ther. 347 (2013), 599–606.
15. Carvalho, C., Santos, R.X., Cardoso, S., Correia, S., Oliveira, P.J., Santos, M.S., Moreira, P.I., Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem. 16 (2009), 3267–3285.
16. Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N.M., Alving, C.R., Muggia, F.M., Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 14 (2003), 1430–1437.
17. Chung, T.K., Warram, J., Day, K.E., Hartman, Y., Rosenthal, E.L., Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol. Ther. 16 (2015), 790–798.
18. Constantinidou, A., Jones, R.L., Scurr, M., Al-Muderis, O., Judson, I., Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur. J. Cancer 45 (2009), 2930–2934.
19. Crivellari, D., Gray, K.P., Dellapasqua, S., Puglisi, F., Ribi, K., Price, K.N., Lang, I., Gianni, L., Spazzapan, S., Pinotti, G., Luthi, J.M., Gelber, R.D., Regan, M.M., Colleoni, M., Castiglione-Gertsch, M., Maibach, R., Rabaglio, M., Coates, A.S., Goldhirsch, A., International Breast Cancer Study Group, Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a standard chemotherapy regimen: the CASA randomized trial. Breast 22 (2013), 130–137.
20. DeVita, T. Jr., Chu, E., A history of cancer chemotherapy. Cancer Res. 68 (2008), 8643–8653.
21. Dellapasqua, S., Mazza, M., Rosa, D., Ghisini, R., Scarano, E., Torrisi, R., Maisonneuve, P., Viale, G., Cassano, E., Veronesi, P., Luini, A., Goldhirsch, A., Colleoni, M., Pegylatedliposomal doxorubicin in combination with low-dose metronomic cyclophosphamide aspreoperative treatment for patients with locally advanced breast cancer. Breast 20 (2011), 319–323.
22. Dobrovolskaia, M.A., Aggarwal, P., Hall, J.B., McNeil, S.E., Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5 (2008), 487–495.
23. Donnem, T., Hu, J., Ferguson, M., Adighibe, O., Snell, C., Harris, A.L., Gatter, K.C., Pezzella, F., Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?. Cancer Med. 2 (2013), 427–436.
24. Duggan, S.T., Keating, G.M., Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs 71 (2011), 2531–2558.
25. Duncan, R., Gaspar, R., Nanomedicine(s) under the microscope. Mol. Pharm. 8 (2011), 2101–2141.
26. Edmonds, S., Volpe, A., Shmeeda, H., Parente-Pereira, A.C., Radia, R., Baguña-Torres, J., Szanda, I., Severin, G.W., Livieratos, L., Blower, P.J., Maher, J., Fruhwirth, G.O., Gabizon, A., de Rosales, T.M.R., Exploiting the metal-chelating properties of the drug cargo for in vivo positron emission tomography imaging of liposomal nanomedicines. ACS Nano(October), 2016 [Epub ahead of print].
27. Ferrandina, G., Corrado, G., Licameli, A., Lorusso, D., Fuoco, G., Pisconti, S., Scambia, G., Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther. Clin. Risk Manage. 6 (2010), 463–483.
28. Fracasso, P.M., Blum, K.A., Ma, M.K., Tan, B.R., Wright, L.P., Goodner, S.A., Fears, C.L., Hou, W., Arquette, M.A., Picus, J., Denes, A., Mortimer, J.E., Ratner, L., Ivy, S.P., McLeod, H.L., Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br. J. Cancer 93 (2005), 46–53.
29. Gabizon, A., Martin, F., Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54:Suppl. 4 (1997), 15–21.
30. Gabizon, A., Papahadjopoulos, D., Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U. S. A. 85 (1988), 6949–6953.
31. Gabizon, A., Dagan, A., Goren, D., Barenholz, Y., Fuks, Z., Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 42 (1982), 4734–4739.
32. Gabizon, A., Meshorer, A., Barenholz, Y., Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst. 77 (1986), 459–469.
33. Gabizon, A., Chisin, R., Amselem, S., Druckmann, S., Cohen, R., Goren, D., Fromer, I., Peretz, T., Sulkes, A., Barenholz, Y., Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64 (1991), 1125–1132.
34. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., Barenholz, Y., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54 (1994), 987–992.
35. Gabizon, A., Chemla, M., Tzemach, D., Horowitz, A.T., Goren, D., Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J. Drug Target. 3 (1996), 391–398.
36. Gabizon, A., Goren, D., Horowitz, A.T., Tzemach, D., Lossos, A., Siegal, T., Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev. 24 (1997), 337–344.
37. Gabizon, A., Horowitz, A.T., Goren, D., Tzemach, D., Mandelbaum-Shavit, F., Qazen, M.M., Zalipsky, S., Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. 10 (1999), 289–298.
38. Gabizon, A., Tzemach, D., Mak, L., Bronstein, M., Horowitz, A.T., Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Target. 10 (2002), 539–548.
39. Gabizon, A., Shmeeda, H., Barenholz, Y., Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42 (2003), 419–436.
40. Gabizon, A.A., Shmeeda, H., Zalipsky, S., Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 16 (2006), 175–183.
41. Gabizon, A., Isacson, R., Rosengarten, O., Tzemach, D., Shmeeda, H., Sapir, R., An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother. Pharmacol. 61 (2008), 695–702.
42. Gabizon, A., Shmeeda, H., Grenader, T., Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur. J. Pharm. Sci. 45 (2012), 388–398.
43. Gabizon, A., Bradbury, M., Prabhakar, U., Zamboni, W., Libutti, S., Grodzinski, P., Cancer nanomedicines: closing the translational gap. Lancet 384 (2014), 2175–2176.
44. Gewirtz, D.A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999), 727–741.
45. Gibson, J.M., Alzghari, S., Ahn, C., Trantham, H., La-Beck, N.M., The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist 18 (2013), 1022–1031.
46. Gil-Gil, M.J., Bellet, M., Morales, S., Ojeda, B., Manso, L., Mesia, C., Garcia-Martinez, E., Martinez-Janez, N., Mele, M., Llombart, A., Pernas, S., Villagrasa, P., Blasco, C., Baselga, J., Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res. Treat. 151 (2015), 597–606.
47. Gordon, A.N., Tonda, M., Sun, S., Rackoff, W., Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95 (2004), 1–8.
48. Grenader, T., Gabizon, A., What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?. J. Clin. Oncol. 28 (2010), e193–e194 (author rely e195-196).
49. Grenader, T., Goldberg, A., Hadas-Halperin, I., Gabizon, A., Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anticancer Drugs 20 (2009), 15–20.
50. Grenader, T., Vernea, F., Reinus, C., Gabizon, A., Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin. J. Clin. Oncol. 29 (2011), e722–724.
51. Haran, G., Cohen, R., Bar, L.K., Barenholz, Y., Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151 (1993), 201–215.
52. Harrington, K.J., Mohammadtaghi, S., Uster, P.S., Glass, D., Peters, A.M., Vile, R.G., Stewart, J.S., Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7 (2001), 243–254.
53. Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94 (2002), 25–36.
54. Hrkach, J., Von Hoff, D., Mukkaram Ali, M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., Low, S., McDonnell, K., Peeke, E., Retnarajan, B., Sabnis, A., Schnipper, E., Song, J.J., Song, Y.H., Summa, J., Tompsett, D., Troiano, G., Van Geen Hoven, T., Wright, J., LoRusso, P., Kantoff, P.W., Bander, N.H., Sweeney, C., Farokhzad, O.C., Langer, R., Zale, S., Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med., 4, 2012, 128ra139.
55. Ilinskaya, A.N., Dobrovolskaia, M.A., Immunosuppressive and anti-inflammatory properties of engineered nanomaterials. Br. J. Pharmacol. 171 (2014), 3988–4000.
56. Ito, K., Hamamichi, S., Asano, M., Hori, Y., Matsui, J., Iwata, M., Funahashi, Y., Umeda, I.O., Fujii, H., Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models. Cancer Sci. 107 (2016), 60–67.
57. Joly, F., Ray-Coquard, I., Fabbro, M., Donoghoe, M., Boman, K., Sugimoto, A., Vaughan, M., Reinthaller, A., Vergote, I., Ferrandina, G., Dell'Anna, T., Huober, J., Pujade-Lauraine, E., Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol. Oncol. 122 (2011), 226–232.
58. Judson, I., Radford, J.A., Harris, M., Blay, J.Y., van Hoesel, Q., le Cesne, A., van Oosterom, A.T., Clemons, M.J., Kamby, C., Hermans, C., Whittaker, J., Donato di Paola, E., Verweij, J., Nielsen, S., Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 37 (2001), 870–877.
59. Kapadia, C.H., Perry, J.L., Tian, S., Luft, J.C., DeSimone, J.M., Nanoparticulate immunotherapy for cancer. J. Control. Release 219 (2015), 167–180.
60. Karathanasis, E., Suryanarayanan, S., Balusu, S.R., McNeeley, K., Sechopoulos, I., Karellas, A., Annapragada, A.V., Bellamkonda, R.V., Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography. Radiology 250 (2009), 398–406.
61. Keller, A.M., Mennel, R.G., Georgoulias, V.A., Nabholtz, J.M., Erazo, A., Lluch, A., Vogel, C.L., Kaufmann, M., von Minckwitz, G., Henderson, I.C., Mellars, L., Alland, L., Tendler, C., Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J. Clin. Oncol. 22 (2004), 3893–3901.
62. Kelly, H., O'Neil, B.H., Response of epithelioid haemangioendothelioma to liposomal doxorubicin. Lancet Oncol. 6 (2005), 813–815.
63. Kinoshita, R., Ishima, Y., Ikeda, M., Kragh-Hansen, U., Fang, J., Nakamura, H., Chuang, V.T., Tanaka, R., Maeda, H., Kodama, A., Watanabe, H., Maeda, H., Otagiri, M., Maruyama, T., S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes. J. Control. Release 217 (2015), 1–9.
64. Kotamraju, S., Kalivendi, S.V., Konorev, E., Chitambar, C.R., Joseph, J., Kalyanaraman, B., Oxidant-induced iron signaling in doxorubicin-mediated apoptosis. Methods Enzymol. 378 (2004), 362–382.
65. Kreuter, A., Rasokat, H., Klouche, M., Esser, S., Bader, A., Gambichler, T., Altmeyer, P., Brockmeyer, N.H., Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Investig. 23 (2005), 653–659.
66. Krown, S.E., Northfelt, D.W., Osoba, D., Stewart, J.S., Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol. 31 (2004), 36–52.
67. La-Beck, N.M., Zamboni, B.A., Gabizon, A., Schmeeda, H., Amantea, M., Gehrig, P.A., Zamboni, W.C., Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother. Pharmacol. 69 (2012), 43–50.
68. Lammers, T., Kiessling, F., Hennink, W.E., Storm, G., Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 161 (2012), 175–187.
69. Lawrie, T.A., Rabbie, R., Thoma, C., Morrison, J., Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. Cochrane Database Syst. Rev., 2013, Cd010482.
70. Lien, M.Y., Liu, L.C., Wang, H.C., Yeh, M.H., Chen, C.J., Yeh, S.P., Bai, L.Y., Liao, Y.M., Lin, C.Y., Hsieh, C.Y., Lin, C.C., Li, L.Y., Lin, P.H., Chiu, C.F., Safety and efficacy of pegylatedliposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer. Anticancer Res. 34 (2014), 7319–7326.
71. Livney, Y.D., Assaraf, Y.G., Rationally designed nanovehicles to overcome cancer chemoresistance. Adv. Drug Deliv. Rev. 65 (2013), 1716–1730.
72. Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N.I., Lotem, M., Brufman, G., Gabizon, A., Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89 (2000), 1037–1047.
73. Lyass, O., Hubert, A., Gabizon, A.A., Phase I study of doxil-cisplatin combinationchemotherapy in patients with advanced malignancies. Clin. Cancer Res. 7 (2001), 3040–3046.
74. Maeda, H., Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91 (2015), 3–6.
75. Maluta, S., Kolff, M.W., Role of hyperthermia in breast cancer locoregional recurrence: a review. Breast Care (Basel) 10 (2015), 408–412.
76. Markiewski, M.M., DeAngelis, R.A., Benencia, F., Ricklin-Lichtsteiner, S.K., Koutoulaki, A., Gerard, C., Coukos, G., Lambris, J.D., Modulation of the antitumor immune response by complement. Nat. Immunol. 9 (2008), 1225–1235.
77. Matsumoto, Y., Nichols, J.W., Toh, K., Nomoto, T., Cabral, H., Miura, Y., Christie, R.J., Yamada, N., Ogura, T., Kano, M.R., Matsumura, Y., Nishiyama, N., Yamasoba, T., Bae, Y.H., Kataoka, K., Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat. Nanotechnol. 11 (2016), 533–538.
78. Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986), 6387–6392.
79. Miller, K., Cortes, J., Hurvitz, S.A., Krop, I.E., Tripathy, D., Verma, S., Riahi, K., Reynolds, J.G., Wickham, T.J., Molnar, I., Yardley, D.A., HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer, 16, 2016, 352.
80. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004), 185–229.
81. Moghimi, S.M., Farhangrazi, Z.S., Just so stories: the random acts of anti-cancer nanomedicine performance. Nanomedicine 10 (2014), 1661–1666.
82. Moghimi, S.M., Szebeni, J., Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42 (2003), 463–478.
83. Moghimi, S.M., Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. J. Control. Release 190 (2014), 556–562.
84. Nagy, J.A., Dvorak, H.F., Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin. Exp. Metastasis 29 (2012), 657–662.
85. Nichols, J.W., Bae, Y.H., EPR: evidence and fallacy. J. Control. Release 190 (2014), 451–464.
86. Nielsen, O.S., Reichardt, P., Christensen, T.B., Pink, D., Daugaard, S., Hermans, C., Marreaud, S., van Glabbeke, M., Blay, J., Judson, I., Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur. J. Cancer 42 (2006), 2303–2309.
87. Northfelt, D.W., Martin, F.J., Working, P., Volberding, P.A., Russell, J., Newman, M., Amantea, M.A., Kaplan, L.D., Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 36 (1996), 55–63.
88. O'Brien, M.E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D.G., Tomczak, P., Ackland, S.P., Orlandi, F., Mellars, L., Alland, L., Tendler, C., C.B.C.S. Group, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15 (2004), 440–449.
89. Oki, Y., Ewer, M.S., Lenihan, D.J., Fisch, M.J., Hagemeister, F.B., Fanale, M., Romaguera, J., Pro, B., Fowler, N., Younes, A., Astrow, A.B., Huang, X., Kwak, L.W., Samaniego, F., McLaughlin, P., Neelapu, S.S., Wang, M., Fayad, L.E., Durand, J.B., Rodriguez, M.A., Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin. Lymphoma Myeloma Leuk. 15 (2015), 152–158.
90. Orlowski, R.Z., Nagler, A., Sonneveld, P., Blade, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, H.J., Suvorov, A.N., Zhuang, S.H., Parekh, T., Xiu, L., Yuan, Z., Rackoff, W., Harousseau, J.L., Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 25 (2007), 3892–3901.
91. Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.D., Woodle, M.C., Lasic, D.D., Redemann, C., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 11460–11464.
92. Park, J.W., Hong, K., Kirpotin, D.B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U.B., Marks, J.D., Moore, D., Papahadjopoulos, D., Benz, C.C., Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8 (2002), 1172–1181.
93. Park, J.W., Benz, C.C., Martin, F.J., Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin. Oncol. 31 (2004), 196–205.
94. Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D., Longhi, R., Allen, T.M., Corti, A., Ponzoni, M., Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63 (2003), 7400–7409.
95. Patil, Y., Amitay, Y., Ohana, P., Shmeeda, H., Gabizon, A., Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: intracellular activation and enhanced cytotoxicity. J. Control. Release 225 (2016), 87–95.
96. Perez-Medina, C., Abdel-Atti, D., Tang, J., Zhao, Y., Fayad, Z.A., Lewis, J.S., Mulder, W.J., Reiner, T., Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nat. Commun., 7, 2016, 11838.
97. Petersen, A.L., Hansen, A.E., Gabizon, A., Andresen, T.L., Liposome imaging agents in personalized medicine. Adv. Drug Deliv. Rev. 64 (2012), 1417–1435.
98. Petersen, G.H., Alzghari, S.K., Chee, W., Sankari, S.S., La-Beck, N.M., Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Control. Release 232 (2016), 255–264.
99. Pham, E., Yin, M., Peters, C.G., Lee, C.R., Brown, D., Xu, P., Man, S., Jayaraman, L., Rohde, E., Chow, A., Lazarus, D., Eliasof, S., Foster, F.S., Kerbel, R.S., Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer. Cancer Res. 76 (2016), 4493–4503.
100. Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., Lombardi, A.V., Febbraro, A., Scollo, P., Ferro, A., Tamberi, S., Brandes, A., Ravaioli, A., Valerio, M.R., Aitini, E., Natale, D., Scaltriti, L., Greggi, S., Pisano, C., Lorusso, D., Salutari, V., Legge, F., Di Maio, M., Morabito, A., Gallo, C., Perrone, F., Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J. Clin. Oncol. 29 (2011), 3628–3635.
101. Prabhakar, U., Maeda, H., Jain, R.K., Sevick-Muraca, E.M., Zamboni, W., Farokhzad, O.C., Barry, S.T., Gabizon, A., Grodzinski, P., Blakey, D.C., Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73 (2013), 2412–2417.
102. Proffitt, R.T., Williams, L.E., Presant, C.A., Tin, G.W., Uliana, J.A., Gamble, R.C., Baldeschwieler, J.D., Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. Science 220 (1983), 502–505.
103. Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P.A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., Sehouli, J., Lortholary, A., Kristensen, G., Jackisch, C., Joly, F., Brown, C., Le Fur, N., du Bois, A., Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28 (2010), 3323–3329.
104. Rayson, D., Suter, T.M., Jackisch, C., van der Vegt, S., Bermejo, B., van den Bosch, J., Vivanco, G.L., van Gent, A.M., Wildiers, H., Torres, A., Provencher, L., Temizkan, M., Chirgwin, J., Canon, J.L., Ferrandina, G., Srinivasan, S., Zhang, L., Richel, D.J., Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Ann. Oncol. 23 (2012), 1780–1788.
105. Regev, R., Yeheskely-Hayon, D., Katzir, H., Eytan, G.D., Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism. Biochem. Pharmacol. 70 (2005), 161–169.
106. Rifkin, R.M., Gregory, S.A., Mohrbacher, A., Hussein, M.A., Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 106 (2006), 848–858.
107. Rios-Doria, J., Durham, N., Wetzel, L., Rothstein, R., Chesebrough, J., Holoweckyj, N., Zhao, W., Leow, C.C., Hollingsworth, R., Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia 17 (2015), 661–670.
108. Rossi, D., Baldelli, A.M., Casadei, V., Fedeli, S.L., Alessandroni, P., Catalano, V., Giordani, P., Ceccolini, M., Graziano, F., Catalano, G., Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. Anticancer Drugs 19 (2008), 733–737.
109. Sabnani, M.K., Rajan, R., Rowland, B., Mavinkurve, V., Wood, L.M., Gabizon, A.A., La-Beck, N.M., Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses. Nanomedicine 11 (2015), 259–262.
110. Schell, R.F., Sidone, B.J., Caron, W.P., Walsh, M.D., White, T.F., Zamboni, B.A., Ramanathan, R.K., Zamboni, W.C., Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. Nanomedicine 10 (2014), 109–117.
111. Schilt, Y., Berman, T., Wei, X., Barenholz, Y., Raviv, U., Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs. Biochim. Biophys. Acta 1860 (2016), 108–119.
112. Seifert, C.F., Nesser, M.E., Thompson, D.F., Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann. Pharmacother. 28 (1994), 1063–1072.
113. Shah, J.J., Orlowski, R.Z., Thomas, S.K., Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther. Clin. Risk Manage. 5 (2009), 151–159.
114. Shapira, A., Livney, Y.D., Broxterman, H.J., Assaraf, Y.G., Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updates 14 (2011), 150–163.
115. Shmeeda, H., Amitay, Y., Gorin, J., Tzemach, D., Mak, L., Stern, S.T., Barenholz, Y., Gabizon, A., Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer. J. Drug Target., 2016, 1–12.
116. Siegal, T., Horowitz, A., Gabizon, A., Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83 (1995), 1029–1037.
117. ® in the presence of ammonia may explain drug release at tumor site. Nanomedicine 11 (2015), 1841–1850.
118. Singal, P.K., Iliskovic, N., Li, T., Kumar, D., Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11 (1997), 931–936.
119. Skubitz, K.M., Haddad, P.A., Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104 (2005), 361–366.
120. Smorenburg, C.H., de Groot, S.M., van Leeuwen-Stok, A.E., Hamaker, M.E., Wymenga, A.N., de Graaf, H., de Jongh, F.E., Braun, J.J., Los, M., Maartense, E., van Tinteren, H., Nortier, J.W., Seynaeve, C., A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann. Oncol. 25 (2014), 599–605.
121. Solomon, R., Gabizon, A.A., Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma 8 (2008), 21–32.
122. Sparano, J.A., Makhson, A.N., Semiglazov, V.F., Tjulandin, S.A., Balashova, O.I., Bondarenko, I.N., Bogdanova, N.V., Manikhas, G.M., Oliynychenko, G.P., Chatikhine, V.A., Zhuang, S.H., Xiu, L., Yuan, Z., Rackoff, W.R., Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J. Clin. Oncol. 27 (2009), 4522–4529.
123. Staropoli, N., Ciliberto, D., Botta, C., Fiorillo, L., Grimaldi, A., Lama, S., Caraglia, M., Salvino, A., Tassone, P., Tagliaferri, P., Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. Cancer Biol. Ther. 15 (2014), 707–720.
124. Straus, D.J., Duvic, M., Horwitz, S.M., Hymes, K., Goy, A., Hernandez-Ilizaliturri, F.J., Feldman, T., Wegner, B., Myskowski, P.L., Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann. Oncol. 25 (2014), 206–210.
125. Suk, J.S., Xu, Q., Kim, N., Hanes, J., Ensign, L.M., PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99 (2016), 28–51.
126. Szebeni, J., Baranyi, L., Savay, S., Bodo, M., Morse, D.S., Basta, M., Stahl, G.L., Bunger, R., Alving, C.R., Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. Heart Circ. Physiol. 279 (2000), H1319–1328.
127. Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bunger, R., Laverman, P., Metselaar, J.M., Storm, G., Chanan-Khan, A., Liebes, L., Muggia, F.M., Cohen, R., Barenholz, Y., Alving, C.R., Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J. Liposome Res. 12 (2002), 165–172.
128. Szebeni, J., Muggia, F., Gabizon, A., Barenholz, Y., Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 63 (2011), 1020–1030.
129. Tahover, E., Patil, Y.P., Gabizon, A.A., Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anticancer Drugs 26 (2015), 241–258.
130. Tan, Q., Saggar, J.K., Yu, M., Wang, M., Tannock, I.F., Mechanisms of drug resistance related to the microenvironment of solid tumors and possible strategies to inhibit them. Cancer J. 21 (2015), 254–262.
131. Theek, B., Baues, M., Ojha, T., Mockel, D., Veettil, S.K., Steitz, J., van Bloois, L., Storm, G., Kiessling, F., Lammers, T., Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. J. Control. Release 231 (2016), 77–85.
132. Torrisi, R., Cardillo, A., Cancello, G., Dellapasqua, S., Balduzzi, A., Ghisini, R., Luini, A., Veronesi, P., Viale, G., Goldhirsch, A., Colleoni, M., Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. Clin. Breast Cancer 10 (2010), 483–488.
133. Torrisi, R., Montagna, E., Scarano, E., Dellapasqua, S., Cancello, G., Iorfida, M., Luini, A., Veronesi, P., Viale, G., Goldhirsch, A., Colleoni, M., Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. Breast 20 (2011), 34–38.
134. Udhrain, A., Skubitz, K.M., Northfelt, D.W., Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int. J. Nanomed. 2 (2007), 345–352.
135. Vaage, J., Barberá‐Guillem, E., Abra, R., Huang, A., Working, P., Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73 (1994), 1478–1484.
136. Vaage, J., Donovan, D., Uster, P., Working, P., Xenografted human pancreatic carcinoma. Br. J. Cancer 75 (1997), 482–486.
137. Vici, P., Colucci, G., Giotta, F., Sergi, D., Filippelli, G., Perri, P., Botti, C., Vizza, E., Carpino, A., Pizzuti, L., Latorre, A., Giannarelli, D., Lopez, M., Di Lauro, L., A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J. Exp. Clin. Cancer Res., 30, 2011, 39.
138. Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M.C., Fossati, R., Gebski, V., Lauraine, E.P., Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br. J. Cancer 107 (2012), 588–591.
139. Wang, B., Galliford, C.V., Low, P.S., Guiding principles in the design of ligand-targeted nanomedicines. Nanomedicine 9 (2014), 313–330.
140. ® gained from “high-sensitivity” differential scanning calorimetry. Eur. J. Pharm. Biopharm. 104 (2016), 260–270.
141. Weiss, A.J., Manthei, R.W., A hypothesis concerning the effect of changes in scheduling upon the cardiotoxicity of adriamycin. Oncology 40 (1983), 223–226.
142. Wollina, U., Dummer, R., Brockmeyer, N.H., Konrad, H., Busch, J.O., Kaatz, M., Knopf, B., Koch, H.J., Hauschild, A., Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (2003), 993–1001.
143. Woodle, M.C., Lasic, D.D., Sterically stabilized liposomes. Biochim. Biophys. Acta 1113 (1992), 171–199.
144. Working, P., Dayan, A., Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum. Exp. Toxicol. 15 (1996), 751–785.
145. ®). J. Liposome Res. 4 (1994), 667–687.
146. Yang, Q., Lai, S.K., Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7 (2015), 655–677.
147. Yang, A., Liu, W., Li, Z., Jiang, L., Xu, H., Yang, X., Influence of polyethyleneglycol modification on phagocytic uptake of polymeric nanoparticles mediated by immunoglobulin G and complement activation. J. Nanosci. Nanotechnol. 10 (2010), 622–628.
148. Yeung, T.K., Chakrabarti, K., Wilding, D., Hopewell, J.W., Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule. Hum. Exp. Toxicol. 21 (2002), 607–614.
149. Zhitomirsky, B., Assaraf, Y.G., Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget 6 (2015), 1143–1156.
150. Zhitomirsky, B., Assaraf, Y.G., Lysosomes as mediators of drug resistance in cancer. Drug Resist. Updates 24 (2016), 23–33.